We use cookies to help provide you with the best possible online experience. Please read our Privacy Policy for information about which cookies we use and what information we collect on our site. By continuing to use this site, you agree that we may store and access cookies on your device.

I Agree

You are here: Industry Insights > Lampit

News List

FDA Approves Lampit for Chagas Disease in Pediatric Patients americanpharmaceuticalreview
August 25, 2020
The U.S. Food and Drug Administration (FDA) approved Lampit (nifurtimox) for the treatment of Chagas disease (American Trypanosomiasis), caused by Trypanosoma cruzi, in pediatric patients (birth to less than 18 years of age and weighing at least 2.5 kg).
US FDA approves Lampit for the treatment of Chagas disease in children pharmaceutical-business-review
August 12, 2020
Bayer announced that the United States Food and Drug Administration (FDA) has approved Lampit (nifurtimox) for use in pediatric patients (from birth to less than 18 years of age and weighing at least 2.5 kg) for the treatment of Chagas disease ...